secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acumen Pharmaceuticals, Inc. (ABOS)
CIK:        0001576885
Form:       8-K
Filed at:   2025-11-10T23:59:59+00:00
Accession:  0001628280-25-050800
Event type: leadership
Sentiment:  positive
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acumen appoints George Golumbeski as Chairman, replaces Sean Stalfort
---------------------------------------------------------------------

- Dr. George Golumbeski appointed as director and Chairman of Board, effective Nov 6, 2025.
- Golumbeski received initial option to buy 50,000 shares at closing price, vesting over 3 years.
- Annual retainer: $40,000 for board service plus $30,000 as Chairman.
- Board now has 8 members; Golumbeski brings 30+ years biopharma experience from Celgene, Novartis.
- Company highlights Phase 2 sabirnetug trial and Enhanced Brain Delivery program as key 2026 catalysts.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1576885/000162828025050800/0001628280-25-050800-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1576885/000162828025050800/abos-20251106.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-050800

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer